key: cord-0743827-1xsdwn8b
authors: Mwimanzi, Francis; Lapointe, Hope R.; Cheung, Peter K.; Sang, Yurou; Yaseen, Fatima; Umviligihozo, Gisele; Kalikawe, Rebecca; Datwani, Sneha; Omondi, F. Harrison; Burns, Laura; Young, Landon; Leung, Victor; Agafitei, Olga; Ennis, Siobhan; Dong, Winnie; Basra, Simran; Lim, Li Yi; Ng, Kurtis; Pantophlet, Ralph; Brumme, Chanson J.; Montaner, Julio S.G.; Prystajecky, Natalie; Lowe, Christopher F.; DeMarco, Mari L.; Holmes, Daniel T.; Simons, Janet; Niikura, Masahiro; Romney, Marc G.; Brumme, Zabrina L.; Brockman, Mark A.
title: Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose
date: 2022-05-11
journal: J Infect Dis
DOI: 10.1093/infdis/jiac199
sha: 6a3239dfcf4bf74637fba2a6e627fe99af482731
doc_id: 743827
cord_uid: 1xsdwn8b

BACKGROUND: Third COVID-19 vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults. METHODS: We measured circulating antibodies against the SARS-CoV-2 spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and Omicron (BA.1) strains from pre-vaccine up to one month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines. RESULTS: Following two vaccine doses, humoral immunity was weaker, less functional and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. One month after the third dose, antibody concentrations and function exceeded post-second-dose levels, and responses in older adults were comparable in magnitude to those in younger adults at this time. Humoral responses against Omicron were universally weaker than against the ancestral strain after both the second and third doses. Nevertheless, after three doses, anti-Omicron responses in older adults reached equivalence to those in younger adults. One month after three vaccine doses, the number of chronic health conditions, but not age, was the strongest consistent correlate of weaker humoral responses. CONCLUSION: Results underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.

Older adults are at increased risk of lethal COVID-19 following SARS-CoV-2 infection [1] [2] [3] . 2 While two COVID-19 mRNA vaccine doses broadly protect against hospitalization and death [4-6], 3 weaker vaccine-induced immunity observed in the elderly and other groups [7-12] led to their 4 prioritization for third doses [13] [14] [15] [16] . Vaccine-induced antibodies also decline over time, which can 5 increase the risk of post-vaccination infections [17] [18] [19] , particularly with the more transmissible and 6 immune evasive Omicron variant [20] [21] [22] . 7 We and others have shown that older age is associated with weaker antibody responses to 8 COVID-19 mRNA vaccines [10] [11] [12] . We previously characterized longitudinal humoral responses up 9 to three months after the second vaccine dose in 151 adults 24 to 98 years of age [12] . Here, we 10 examine binding and neutralizing antibody responses up to six months post-second-dose, and at one 11 month post-third-dose. We also evaluate binding antibodies, ACE2 displacement, and virus 12 neutralization against Omicron (BA.1). Characterization of the immunological benefits of a third dose 13 is critical to promote continued public uptake, particularly in light of recent Omicron-driven infection 14 waves.

Study design. We conducted a prospective longitudinal cohort study in British Columbia, Canada, to 17 examine SARS-CoV-2 specific humoral responses following vaccination with Comirnaty (BNT162b2 -18 BioNTech/Pfizer) or Spikevax (mRNA-1273-Moderna). Our cohort (total n=151) included 81 19 healthcare workers (HCW) and 56 older adults (including 18 residents of long-term care or assisted 20 living facilities) who were COVID-19 naive at study entry, and 14 individuals (including 8 HCW and 6 21 older adults) with anti-SARS-CoV-2 nucleocapsid (N) antibodies at study entry (COVID-19 22 convalescent group) [12] . Serum and plasma were collected prior to vaccination; one month after the 23 A C C E P T E D M A N U S C R I P T 6 first dose; one, three and six months after the second dose; and one month following the third dose (see 1   Table 1 for exact collection timings) [12] . Data sources. Sociodemographic, health and vaccine information was collected by self-report and 6 confirmed through medical records where available. Chronic health conditions were defined as 7 hypertension, diabetes, asthma, obesity (body mass index ≥30), chronic diseases of lung, liver, kidney, 8 heart or blood, cancer, and immunosuppression due to chronic conditions or medication, to generate a 9 score ranging from 0-11 per participant [12] .

10 Binding antibody assays. We measured total binding antibodies against SARS-CoV-2 N and spike (S) 11 receptor binding domain (RBD) in serum using the Roche Elecsys Anti-SARS-CoV-2 and Anti-SARS- 12 CoV-2 S assays, respectively, on a Cobas e601 module analyzer (Roche Diagnostics). Following standard. For the S assay, the manufacturer indicates that AU values can be considered equivalent to 17 World Health Organization-defined international binding antibody units (BAU) [23] . For the S assay, 18 sera were tested undiluted, with samples above the upper limit of quantification (ULOQ) re-tested at 19 1:100 dilution, allowing an 0.4 -25,000 U/mL measurement range. We also quantified plasma IgG 20 binding antibodies against RBD using the V-plex SARS-CoV-2 (IgG) Panel 22 ELISA kit (Meso Scale 21 Diagnostics), which features the ancestral (Wuhan) and Omicron (BA.1) RBD antigens, on a Meso activity is reported as the highest reciprocal plasma dilution able to prevent CPE in all three wells. 14 Samples exhibiting partial or no neutralization at 1/20 dilution were coded as below the limit of 15 quantification (BLOQ) in this assay.

Statistical analysis. Comparisons of binary variables were performed using Fisher's exact test. 17 Comparisons of continuous variables were performed using the Mann-Whitney U-test (for unpaired 18 data) or Wilcoxon test (for paired data). Multiple linear regression was used to investigate the 19 relationship between sociodemographic, health and vaccine-related variables, and humoral outcomes. 20 Variables included age (per year), sex at birth (female as reference group), ethnicity (non-white as 21 reference), number of chronic health conditions (per additional), mRNA vaccine received (Comirnaty 22 as reference), interval between doses (per day), sampling date following the most recent dose (per day),

and convalescent status (COVID-19 naive as reference). Binding antibody and viral neutralization-1 related dependent variables were log-transformed prior to model input. Independent variables were 2 examined for multi-collinearity by calculating the bivariate correlation between all pairs of variables. 3 Here, coefficients <-0.75 or >0.75 would have been considered highly collinear, however no variables 4 in any model met this threshold. No interaction terms were considered. Serum antibody half-lives were 5 calculated by fitting exponential curves to antibody concentrations at one, three and six months post-6 second dose. All tests were two-tailed, with p<0.05 considered statistically significant. Analyses were 7 conducted using Microsoft Excel and Prism v9.2.0 (GraphPad).

Participant characteristics 10 HCW, older adults and COVID-19 convalescent individuals were a median of 41, 79 and 48 11 years old, respectively, and predominantly female ( Table 1) . Older adults were predominantly (77%) After two-dose vaccination, lower binding antibodies are associated with older age and chronic 5 conditions, but older adults mount strong third-dose responses 6 We measured total anti-RBD binding antibody concentrations in serum before and after 7 immunization ( Figure 1A) . As reported previously [12] , antibody concentrations in older adults were (Table S1 ). One month post-second dose for 4 example, each decade of older age was associated with an ~0.06 log 10 lower antibody concentration 5 (p=0.0067). A higher number of chronic conditions was also independently associated with lower 14 In both HCW and older adults, the third dose boosted antibody concentrations at least ~0.3-0.4 15 log 10 higher than peak values observed after two doses (Wilcoxon paired test p<0.0001 for both 16 groups). Binding antibodies in HCW rose to a median of 4.31 (IQR 4.13 to upper limit of quantification 17 [ULOQ]) while those in older adults rose to a median of 4.33 (4.14 to ULOQ) (p=0.33), indicating that 18 older and younger adults mounted comparable initial binding antibody responses to third doses. In 19 multivariable analyses of third-dose responses, a higher number of chronic conditions was the sole 20 significant correlate of lower antibody concentrations (p=0.0078), while having received a Spikevax 21 third dose was associated with higher antibody concentrations (p=0.0091) ( Table S2) . 2 We next (USA-quantified the ability of plasma to prevent target cell infection by the ancestral after the second dose, neutralizing activity had declined to below the limit of quantification (BLOQ) in 13 58% of HCW and 83% of older adults (Mann-Whitney p=0.0048 for comparison between groups). 14 COVID-19 convalescent individuals by contrast maintained significantly higher neutralizing activity 15 compared to naive individuals at all time points following two-dose vaccination. Multivariable analyses 16 confirmed that older age remained significantly associated with weaker neutralizing activity at one and 17 three months after two-dose vaccination, while COVID-19 convalescent status was associated with 18 superior neutralization at all time points following two-dose vaccination (all p≤0.0002) ( Table S1) . 19 A third vaccine dose boosted neutralizing activity in both HCW and older adults to levels that 20 were two-and eight-fold higher than peak post-second dose values, respectively (Wilcoxon paired test 21 p≤0.006 for both groups; Figure 1B) . Specifically, the median reciprocal dilution in HCW and older 22 adults rose to 320 [IQR 160-320] and 320 [IQR 80-320], respectively (p=0.6), indicating that older

adults mounted comparable initial neutralizing responses to younger adults post-third dose. A 1 multivariable analysis identified prior COVID-19 as the strongest independent predictor of higher 2 neutralization post-third dose (p=0.0044; Table S2 ). 3 Chronic conditions are associated with faster binding antibody decline after two vaccine doses 4 We next assessed antibody decline after two-dose vaccination (Figure 2A) . Assuming 5 exponential decay and restricting the analysis to participants with a complete longitudinal data series 6 with no values above the ULOQ, we estimated antibody concentration half-lives to be a median of 59 7 [IQR 52-75] days in HCW versus a median of 52 [IQR 45-65] days in older adults (p=0.016; Figure   8 2B). This suggests that, in addition to overall weaker responses to two-dose vaccination compared to 9 younger adults, antibody concentrations in older adults also decline more rapidly. In multivariable 10 analyses however, a higher number of chronic conditions emerged as the sole independent correlate of 11 antibody decline, with each additional condition associated with a 5-day shorter half-life (p=0.017; 12 Table 2 ). COVID-19 convalescent status was associated with a 14-day longer antibody half-life after 13 adjustment for other factors (p=0.056), consistent with more durable hybrid immunity [29-31].

14 Omicron-specific humoral responses 15 Given the rise of Omicron, we compared peak antibody responses against this strain in plasma 16 at one month post-second and third vaccine doses. Here, all participants with prior COVID-19, 17 regardless of infection timing, were included in the convalescent category. Overall, Omicron-specific 18 anti-RBD IgG binding antibodies, measured using the Meso Scale Diagnostics V-Plex assay, were on 19 average 0.4 to 0.5 log 10 U/mL lower than those against the wild type (WT; ancestral Wuhan strain) 20 RBD after two and three doses (all within-group comparisons p≤0.0002; Figure 3A) . Nevertheless, the 21 third dose universally boosted Omicron-specific anti-RBD IgG concentrations to an average of 0.5 22 log 10 higher than levels induced by two doses (all within-group comparisons p<0.05). Consistent with

total anti-RBD binding antibody concentrations quantified using the Roche assay (Figure 1A) , anti-1 RBD IgG concentrations against WT were significantly higher in HCW compared to older adults after 2 two doses (p<0.0001) but reached equivalence after three doses (p=0.4) ( Figure 3A) . The latter result 3 further confirms that initial third-dose binding antibody responses were comparable in older and 4 younger adults (as higher dilutions used in the Meso Scale assay allow quantification over a larger 5 dynamic range than the Roche assay). 6 Omicron-specific anti-RBD IgG concentrations followed a similar pattern, with HCW showing 7 marginally higher levels compared to older adults after two doses (p=0.09), but equivalent levels after 8 three doses (p=0.49). A multivariable analysis of Omicron-specific anti-RBD IgG concentrations post-9 third dose identified a higher number of chronic conditions as the strongest correlate of poorer 10 responses, with each additional condition associated with a 0.12 log 10 lower response (p=0.0033; Table   11 3). A longer interval between the first and second vaccine doses was marginally associated with a 12 lower third dose response (p=0.02). 13 We also assessed the ability of plasma to block the interaction between WT and Omicron RBD 14 and the cellular ACE2 receptor using a competition assay. This activity was significantly weaker 15 against Omicron compared to WT after both two and three doses in all groups (all within-group 16 comparisons p≤0.0002; Figure 3B ), though the discrepancy was most pronounced for older adults after 17 two doses (where median anti-WT activity was 90% compared to 23% against Omicron). The third 18 dose universally boosted ACE2 competition activity against Omicron (all within-group comparisons 19 p<0.05), with, for example, median activity in older adults rising to 66% (from 23%). Consistent with 20 results for anti-RBD IgG antibodies, plasma ability to block the WT-RBD/ACE2 interaction was 21 significantly higher in HCW compared to older adults after two doses (p<0.0001), but reached 22 equivalence after three doses (in fact, activities in older adults were slightly higher at this time point;

p=0.08). Ability to block the Omicron-RBD/ACE2 interaction followed a similar pattern, with HCW 1 exhibiting significantly higher activity compared to older adults after two doses (p<0.0001), but 2 equivalent levels after three doses (p=0.2). In multivariable analyses, a higher number of chronic 3 conditions was the strongest correlate of poorer Omicron-specific ACE2 competition activity after 4 three vaccine doses, with each additional condition associated with a ~6% reduction in this activity 5 (p=0.0046; Table 3 ). Male sex, a longer interval between the first and second doses, and days elapsed 6 since the third dose also correlated with weaker post-third dose responses (all p<0.05).

Finally, we compared plasma neutralization of WT and Omicron strains using a live virus assay 8 in a subset of 20 HCW and 21 older adults who remained COVID-19 negative throughout the study 9 (Figure 4) . Neutralizing activity against Omicron was significantly weaker than that against WT 10 following two and three doses in both groups (all p<0.0001). The third dose nevertheless boosted 11 Omicron-specific neutralization in both groups, where the increase in older adults was particularly 12 pronounced (from a median of BLOQ after the second dose to a median reciprocal dilution of 40 after 13 the third; p<0.0001). Consistent with anti-RBD IgG and ACE2 competition results, Omicron-specific 14 neutralization was significantly lower in older adults compared to HCW after two vaccine doses 15 (p=0.0003) but reached equivalence after three doses (p=0.79).

At one, three and six months following two-dose COVID-19 mRNA vaccination, antibody 18 binding and neutralizing activity were significantly weaker in older compared to younger adults.

Antibody concentrations were also less durable in older adults, though responses declined substantially 20 in all groups over time (e.g. by six months post-second dose, neutralization had declined to BLOQ in 21 almost 60% of HCW and >80% of older adults). In multivariable analyses, a higher number of chronic Our study has several limitations. As the precise immune correlates of protection for SARS- In conclusion, while the observation of strong initial binding and neutralizing antibody 7 responses to third COVID-19 vaccine doses in older adults, including to Omicron, are encouraging, it 8 will be important to closely monitor third-dose response durability in this population. 9 ACKNOWLEDGEMENTS 10 We thank the leadership and staff of Providence Health Care, including long-term care and 11 assisted living residences, for their support of this study. We thank the phlebotomists and laboratory neutralization in fewer than three wells at a 1/20 dilution were coded as LLOQ. The highest dilution 1 tested was 1/2560, which corresponds to the ULOQ. Note that only a subset of pre-vaccine plasma 2 samples was assayed for this activity. were computed using the Mann-Whitney U-test and are uncorrected for multiple comparisons. COVID-19 post-vax Anti-N seroconversion during study follow-up 6 (7.4%) 2 (3.6%) a interquartile range b denominators are the n of specimens collected one month after third dose 

COVID-19) in Long-term Care Facilities 3 in Ontario, Canada

Older age and frailty are the chief predictors of 5 mortality in COVID-19 patients admitted to an acute medical unit in a secondary care setting-a cohort 6 study

Estimating excess 1-year mortality associated with the COVID-8 19 pandemic according to underlying conditions and age: a population-based cohort study

Efficacy and Safety of the mRNA-1273 SARS-CoV-2

Safety and Efficacy of the BNT162b2 mRNA Covid-19

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass 15 Vaccination Setting

Reduced humoral response to mRNA SARS-CoV-2

BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus

Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

Effectiveness of a third dose of the BNT162b2 mRNA COVID-11 19 vaccine for preventing severe outcomes in Israel: an observational study

Protection of BNT162b2 Vaccine Booster against 14

Covid-19 in Israel

SARS-CoV-2 Neutralization with BNT162b2 Vaccine 16 Dose 3

Early Immunogenicity and Safety of the Third 18

Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 19 Years: Real-World Experience

Correlation of SARS-CoV-2-breakthrough infections to 21

Omicron variant showed lower neutralizing sensitivity than other

SARS-CoV-2 variants to immune sera elicited by vaccines after boost

Increased Potency and Breadth of SARS-CoV-2 Neutralizing 4

Antibodies After a Third mRNA Vaccine Dose

SARS-CoV-2 Omicron Variant Neutralization after 7 mRNA-1273 Booster Vaccination

An Advisory Committee Statement 9 (ACS) National Advisory Committee on Immunization (NACI): Guidance on booster COVID-19 10 vaccine doses in Canada -Update

An immunodominant NP105-113-B*07:02 cytotoxic T cell 14 response controls viral replication and is associated with less severe COVID-19 disease

Pre-existing polymerase-specific T cells expand in 17 abortive seronegative SARS-CoV-2

SARS-CoV-2 human T cell epitopes: Adaptive immune response 19 against COVID-19

Immunological memory to SARS-CoV-2 assessed for up to 8 21 months after infection

Escape from recognition of SARS-CoV-2 variant spike 1 epitopes but overall preservation of T cell immunity

Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent 4 Individuals

T cell responses to SARS-CoV-2 spike cross-recognize

Vaccines elicit highly conserved cellular immunity to 8 SARS-CoV-2 Omicron

Comparison of SARS-CoV-2 Antibody 10

Response Following Vaccination With BNT162b2 and mRNA-1273

Effectiveness of Pfizer-BioNTech and Moderna Vaccines 12 in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread 13 Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National Healthcare Safety Network